Business UpdateJun 9, 2026, 08:01 AM
Incannex Healthcare Initiates AGP Coverage with BUY Rating, $18 Target
AI Summary
Incannex Healthcare Inc. announced that Alliance Global Partners (AGP) has initiated equity research coverage of the company. AGP assigned a "BUY" rating and a price target of US$18.00 per share. Incannex believes this coverage will expand awareness of its clinical programs, including IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder, and its investment proposition among investors.
Key Highlights
- Alliance Global Partners (AGP) initiated equity research coverage of Incannex Healthcare Inc.
- AGP assigned a "BUY" rating to Incannex Healthcare Inc.
- AGP set a price target of US$18.00 per share for Incannex Healthcare Inc.
- The research report was authored by James Molloy, AGP Managing Director and Senior Biotechnology Analyst.
- The report discusses Incannex's lead obstructive sleep apnoea program, IHL-42X.
- The report also covers PSX-001, the synthetic psilocybin program for generalized anxiety disorder.
Price Impact
More from IXHL